Northwestern Mutual Wealth Management Co. Grows Stake in Insmed, Inc. $INSM

Northwestern Mutual Wealth Management Co. raised its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 8,017.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,254 shares of the biopharmaceutical company’s stock after buying an additional 9,140 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Insmed were worth $1,611,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. CIBC Private Wealth Group LLC grew its holdings in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new stake in Insmed during the 4th quarter valued at $27,000. SBI Securities Co. Ltd. grew its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the last quarter. GraniteShares Advisors LLC acquired a new stake in Insmed during the 4th quarter valued at $30,000. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in Insmed by 169.7% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 151 shares during the last quarter.

Insmed Price Performance

INSM stock opened at $106.40 on Thursday. Insmed, Inc. has a 52-week low of $65.56 and a 52-week high of $212.75. The stock’s fifty day simple moving average is $135.85 and its 200-day simple moving average is $159.04. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $23.06 billion, a price-to-earnings ratio of -18.50 and a beta of 0.89.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The business had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter last year, the firm earned ($1.42) earnings per share. The business’s revenue was up 229.7% on a year-over-year basis. Equities research analysts expect that Insmed, Inc. will post -2.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on INSM. Mizuho increased their target price on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Truist Financial lowered their target price on Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Royal Bank Of Canada lowered their target price on Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. HC Wainwright reiterated a “buy” rating on shares of Insmed in a report on Friday, May 8th. Finally, Barclays increased their target price on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $210.95.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $108.47, for a total value of $666,982.03. Following the completion of the transaction, the insider directly owned 41,613 shares in the company, valued at $4,513,762.11. This trade represents a 12.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 156,643 shares of company stock worth $24,513,766 over the last quarter. 2.10% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.